Outcome of lupus nephritis patients treated with an anti-CD40 monoclonal antibody according to kidney biopsy features.

Autor: Uzzo M; Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.; Department of Pathology and Medical Biology, University of Groningen, University Medical Center, Groningen, The Netherlands., Schumacher H; Statistical Consultant, Ingelheim, Germany., Steffgen J; Boehringer Ingelheim International GmbH, Biberach, Germany., Deutschel S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Jayne D; Department of Medicine, University of Cambridge, Cambridge, UK., Bajema I; Department of Pathology and Medical Biology, University of Groningen, University Medical Center, Groningen, The Netherlands.

Publikováno v: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2024 Dec 08. Date of Electronic Publication: 2024 Dec 08.

Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

Autor: Jayne DR; Department of Medicine, University of Cambridge, Cambridge, UK., Steffgen J; Boehringer Ingelheim International GmbH, Biberach, Germany., Romero-Diaz J; Instituto Nacional de Ciencias Médicas y Nutrición 'Salvador Zubiran', Mexico City, Mexico., Bajema I; Department of Pathology and Medical Biology, University of Groningen, University Medical Center, Groningen, the Netherlands., Boumpas DT; Department of Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece., Noppakun K; Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Amano H; Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Gomez HM; Angeles University Foundation Medical Center, Angeles City, Philippines., Satirapoj B; Division of Nephrology, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand., Avihingsanon Y; Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Chawanasuntorapoj R; Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand., Madero M; National Institute of Cardiology Ignacio Chávez, Mexico City, Mexico., Naumnik B; Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland., Recto R; Mary Mediatrix Medical Center, Lipa City, Philippines., Fagan N; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut., Revollo I; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Wu J; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut., Visvanathan S; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut., Furie R; Northwell Health and Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York.

Publikováno v: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2023 Nov; Vol. 75 (11), pp. 1983-1993. Date of Electronic Publication: 2023 Aug 17.

Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.

Autor: Litzenburger T; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Steffgen J; Boehringer Ingelheim International GmbH, Biberach, Germany., Benediktus E; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Müller F; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Schultz A; CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany., Klein E; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA., Ramanujam M; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA., Harcken C; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA., Gupta A; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA., Wu J; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA., Wiebe S; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Li X; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA., Flack M; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA., Padula SJ; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Visvanathan S; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA., Hünnemeyer A; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Hui J; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2021 Apr; Vol. 87 (4), pp. 1824-1838. Date of Electronic Publication: 2020 Nov 20.

Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis.

Autor: Ramanujam M; Immunology & Respiratory Diseases Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; Institute of Infection, Immunity and Inflammation, University of Glasgow, UK. Electronic address: meera.ramanujam@boehringer-ingelheim.com., Steffgen J; TA Inflammation Medicine, Boehringer Ingelheim, International GmbH, Biberach, Germany; Department of Nephrology and Rheumatology, Georg-August University of Göttingen, Göttingen, Germany., Visvanathan S; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA., Mohan C; Department of Biomedical Engineering, University of Houston, Houston, TX, USA., Fine JS; Immunology & Respiratory Diseases Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA., Putterman C; Albert Einstein College of Medicine, Bronx, NY, USA; Azrieli School of Medicine, Bar-Ilan Universtiy, Zefat, Israel; Research Institute, Galilee Medical Center, Nahariya, Israel. Electronic address: chaim.putterman@einstein.yu.edu.

Publikováno v: Autoimmunity reviews [Autoimmun Rev] 2020 Nov; Vol. 19 (11), pp. 102668. Date of Electronic Publication: 2020 Sep 14.

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.

Autor: Visvanathan S; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA sudha.visvanathan@boehringer-ingelheim.com., Daniluk S; ClinicMed Badurski and Partners, Białystok, Poland., Ptaszyński R; Rheumatica, Warsaw, Poland., Müller-Ladner U; Justus Liebig University Giessen, Bad Nauheim, Germany., Ramanujam M; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA., Rosenstock B; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Eleftheraki AG; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Vinisko R; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA., Petříková A; CTCenter MaVe, Olomouc, Czech Republic., Kellner H; Centre for Inflammatory Joint Diseases, Munich, Germany., Dokoupilova E; Medical Plus, s.r.o, Uherské Hradiště, Czech Republic.; Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic., Kwiatkowska B; Prof. Eleonora Reicher Memorial National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland., Alten R; Schlosspark-Klinik, Berlin, Germany., Schwabe C; Auckland Clinical Studies, Auckland, New Zealand., Baum P; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Joseph D; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA., Fine JS; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA., Padula SJ; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Steffgen J; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2019 Jun; Vol. 78 (6), pp. 754-760. Date of Electronic Publication: 2019 Mar 22.